Trial · NCT00781859
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
NCT00781859, Phase 3, Completed, ThromboGenics; results first posted 2013-01-28
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial. Trials, record NCT00781859. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00781859
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
- NCT number
- NCT00781859
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 326 participants, actual
- Lead sponsor
- ThromboGenics
- Conditions
- Vitreomacular Adhesion
- Interventions
- 125 µg Ocriplasmin, Placebo
- First posted
- 2008-10-29
- Last updated
- 2014-12-17
- Results first posted
- 2013-01-28
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28. | Day 28 | The primary efficacy endpoint was the proportion of subjects with nonsurgical resolution of focal vitreomacular adhesion at Day 28 post-injection, as determined by masked Central Reading Center (CRC) Optical Coherence Tomography (OCT) evaluation. Any subjects who had a creation of an anatomical defect (i.e. retinal hole, retinal detachment) that resulted in loss of vision or that required additional intervention were not counted as successes for this primary endpoint. |
| Secondary | Proportion of Subjects With Total Posterior Vitreous Detachment (PVD) at Day 28 | Day 28 | The key secondary endpoint of this study was the proportion of subjects with total Posterior Vitreous Detachment (PVD) at Day 28, as determined by masked Investigator assessment of B-scan ultrasound. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28. | Day 28 | Intention-To-Treat (ITT), Last Observation Carried forward (LOCF) | percentage of participants | NUMBER |
| SECONDARY | Proportion of Subjects With Total Posterior Vitreous Detachment (PVD) at Day 28 | Day 28 | Intention-To-Treat (ITT, Last Observation Carried Forward (LOCF) | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28. | Ocriplasmin 125µg | 27.9 | percentage of participants | ||
| Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28. | Placebo | 13.1 | percentage of participants | ||
| Proportion of Subjects With Total Posterior Vitreous Detachment (PVD) at Day 28 | Ocriplasmin 125µg | 16.4 | percentage of participants | ||
| Proportion of Subjects With Total Posterior Vitreous Detachment (PVD) at Day 28 | Placebo | 6.5 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ocriplasmin 125µg | 219 | |
| Overall Study | STARTED | Placebo | 107 | |
| Overall Study | COMPLETED | Ocriplasmin 125µg | 200 | |
| Overall Study | COMPLETED | Placebo | 98 | |
| Overall Study | NOT COMPLETED | Ocriplasmin 125µg | 19 | |
| Overall Study | NOT COMPLETED | Placebo | 9 |
Source ClinicalTrials.gov
Adverse events56
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vitreous floaters | Eye disorders | Ocriplasmin 125µg | 44 | 220 | 49 |
| other | Vitreous floaters | Eye disorders | Placebo | 10 | 106 | 10 |
| other | Conjunctival Hemorrhage | Eye disorders | Ocriplasmin 125µg | 34 | 220 | 35 |
| other | Conjunctival Hemorrhage | Eye disorders | Placebo | 14 | 106 | 14 |
| other | Photopsia | Eye disorders | Ocriplasmin 125µg | 37 | 220 | 40 |
| other | Photopsia | Eye disorders | Placebo | 4 | 106 | 4 |
| other | Eye pain | Eye disorders | Ocriplasmin 125µg | 34 | 220 | 39 |
| other | Eye pain | Eye disorders | Placebo | 6 | 106 | 6 |
| other | Vision blurred | Eye disorders | Ocriplasmin 125µg | 25 | 220 | 27 |
| other | Vision blurred | Eye disorders | Placebo | 5 | 106 | 7 |
1 to 10 of 56Source ClinicalTrials.gov
See all 56 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ocriplasmin 125µg | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Ocriplasmin 125µg | 127 | 220 |
| Total, other adverse events | Placebo | 35 | 106 |
| Total, serious adverse events | Ocriplasmin 125µg | 32 | 220 |
| Total, serious adverse events | Placebo | 13 | 106 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Ocriplasmin 125µg vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00781859
GET https://conductscience.org/api/trials/v1/NCT00781859/events?page=2